The research indicates that Sishen Pills (Zhao et al., 2019) and their active metabolites, schisandrin B (Zhang et al., 2021a), schisandrin (Wang et al., 2023d), evodiamine (Kim et al., 2019; Shen et al., 2019; Ding et al., 2020), and rutaecarpine (Byun et al., 2022) could affect cell fate by regulating the NLRP3 and Wnt signaling pathways, thus offering a therapeutic role in IBD and colon cancer. Here, NLRP3 is linked to malignant colon neoplasm.